382

Search

Sign in or sign up

Register

Incuron, LLC

Incuron, LLC is a Russian Federation based joint venture founded in January 2010 between Russian Closed Mutual Venture Fund "Bioprocess Capital Ventures", and Cleveland BioLabs. Incuron, LLC is developing an innovative pipeline of drugs to treat oncology for the global markets.

Incuron Announces Notice of Allowance from FDA to Commence Clinical Trials of CBL0137.

27.11.2015 Incuron announces the receipt of a Notice of Allowance from the U.S. Food and Drug Administration (FDA) for an Investigational New Drug (IND) application (#124239) for CBL0137.

Results in Study of Pediatric Neuroblastoma

17.11.2015 Incuron Announces Results in Study of Pediatric Neuroblastoma, that have been published in the journal Science Translational Medicine. The reported studies were led by scienti

Incuron Announces Updates on Clinical Progress with CBL0137

09.02.2015 Incuron, a joint subsidiary of the Bioprocess Capital Ventures closed-end investment fund and Cleveland BioLabs, Inc., announced updates on clinical progress with lead oncology p

Latest news

Incuron Announces Notice of Allowance from FDA to Commence Clinical Trials of CBL0137.

27.11.2015 Incuron announces the receipt of a Notice of Allowance from the U.S. Food and Drug Admin

Results in Study of Pediatric Neuroblastoma

17.11.2015 Incuron Announces Results in Study of Pediatric Neuroblastoma, that have been published

Incuron Announces Updates on Clinical Progress with CBL0137

09.02.2015 Incuron, a joint subsidiary of the Bioprocess Capital Ventures closed-end investment fun

Incuron, LLC Announces the Successful Completion of a Phase 1 Study of CBL0102

15.01.2012 Incuron, LLC Announces the Successful Completion of a Phase 1 Study of CBL0102 Incuron,

Science Translational Medicine Publishes Breakthrough Finding From Cleveland BioLabs and Incuron on Identification of Target and Mechanism of Action of Novel Anticancer Agents Curaxins

09.06.2013 BUFFALO, NY--(Marketwire - Aug 10, 2011) - Cleveland BioLabs, Inc. (NASDAQ: CBLI) a

Incuron, LLC Announces Start of US Trial With CBL0137

The primary objective of the study is to determine the maximally tolerated dose and recommend a Phas

Incuron Announces Updates on Clinical Progress with CBL0137

09.02.2015 Incuron, a joint subsidiary of the Bioprocess Capital Ventures closed-end investment fun

Incuron, LLC announces start of a phase Ib safety and tolerability trial for curaxin CBL0102 in patients with liver tumors of different etiology in Russia

The study is a multicenter open-label, dose escalation, Phase 1b safety and tolerability study in pa

With the support of the innovation center Skolkovo

About us

Incuron, LLC is a Russian Federation based joint venture founded in January 2010 between Russian Closed Mutual Venture Fund "Bioprocess Capital Ventures", and Cleveland BioLabs.

Incuron, LLC is developing an innovative pipeline of drugs to treat oncology for the global markets.

Video

You are here:   HomeHome